TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26348533
Drug: Oral inhalation
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation of olodaterol (2.5-70 μg via Respimat® inhaler)
Study: 17981449
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1.84 g/day of EPA and DHA)
Study: 16439505
Drug: Auto-crosslinked hyaluronan
Normalized name: hyaluronic acid, crosslinked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-crosslinked hyaluronan gel
Study: 25547983
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet rich plasma (PRP) treatment
Study: 18416281
Drug: Levetiracetam (250,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (250, 500, or 1000 mg, single dose) after acetylsalicylic acid (aspirin)
Study: 18416281
Drug: Levetiracetam (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (twice daily for 4 days) with aspirin administered with the penultimate dose
Study: 18416281
Drug: Levetiracetam (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (twice daily for 4.5 days)
Study: 18416281
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 4.5 days)
Study: 8872417
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of tacrine
Study: 8872417
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day of tacrine
Study: 8872417
Drug: tacrine (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrine (dosage not specified) with lecithin
Study: 1804294
Drug: Psoralen plus
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen plus ultraviolet A (PUVA) therapy, oral psoralen (8‐methoxypsoralen; 0.6 mg/kg) taken at each session, 10-20 sessions 3 times per week
Study: 1804294
Drug: Psoralen plus
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen plus ultraviolet A (PUVA) therapy
Study: 6318350
Drug: Bi‐Profenid 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi‐Profenid 150 mg
Study: 31980156
Drug: Peri-hamstring local
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-hamstring local anaesthetic injection (Group H)
Study: 30935601
Drug: Interactive power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interactive power toothbrush (Oral-B Professional Care 6000, D36/EB20) with Bluetooth technology
Study: 30935601
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B Indicator 35 soft)
Study: 22867036
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill plus behavioral support
Study: 20168306
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (240 mg/day)
Study: 10574423
Drug: ramipril-felodipine ER
Normalized name: felodipine / ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril-felodipine ER (10/10 mg)
Study: 10574423
Drug: ramipril-felodipine ER
Normalized name: felodipine / ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril-felodipine ER (5/5 mg)
Study: 10574423
Drug: felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine ER monotherapy
Study: 25304277
Drug: Subconjunctival preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival preparation of 6×6 mm (group A)
Study: 25304277
Drug: Subconjunctival preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival preparation of 8×9 mm (group B)
Study: 21684018
Drug: Web-camera delivered
Normalized name: Calmera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-camera delivered cognitive-behavioral therapy (W-CBT)
Study: 18008156
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH commenced in the luteal phase with a long GnRH agonist protocol
Study: 18008156
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received FSH on day 2 in a short protocol GnRH agonist regimen
Study: 11278211
Drug: Ganirelix (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (0.25 mg, s.c.)
Study: 11278211
Drug: Triptorelin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (0.1 mg, s.c.)
Study: 3075434
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg orally twice a day)
Study: 3075434
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg orally twice a day)
Study: 19104202
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy for metastatic breast cancer
Study: 28697910
Drug: Duphaston (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duphaston (20 mg/d)
Study: 28697910
Drug: Utrogestan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan (100 mg/d)
Study: 25577227
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (health education and tilt training) plus ORS (with 500 ml of water) - Group I (87 patients)
Study: 25577227
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy - Group II (79 patients)
Study: 18931845
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonist (VKA) for 30 months
Study: 18931845
Drug: Discontinue Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue Vitamin K Antagonist (VKA) after 6 months
Study: 16732017
Drug: Ramipril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25 mg o.d.)
Study: 15353428
Drug: Faxed physician
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faxed physician reminders containing osteoporosis treatment guidelines and patient education
Study: 10755330
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin 5 to 30mg once daily
Study: 10755330
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin 15mg once daily
Study: 8173166
Drug: Immediate platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate platinum-based therapy
Study: 8173166
Drug: Platinum in
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum in combination
Study: 3669080
Drug: Marital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marital therapy combined with symptom-specific therapy for sexual dysfunction
Study: 3669080
Drug: Relaxation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation and information before sex therapy
Study: 31003664
Drug: Yoga nidra
Normalized name: Mycogone nigra
DrugBank: Mycogone nigra (DB10971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga nidra (1-hour sessions, bi-weekly for 8 weeks)
Study: 28870177
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Tripterygium wilfordii Hook F gel
Study: 19920114
Drug: Dasatinib 70
Normalized name: dasatinib 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 70 mg twice daily
Study: 15363067
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IGF‐I (0.05 mg/kg twice daily by subcutaneous injection)
Study: 9700998
Drug: Cilnidipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (5 or 10 mg once daily)
Study: 9673431
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (10 or 20 mg twice daily)
Study: 8090335
Drug: Diltiazem 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 0.3 mg/kg bolus preoperatively, followed by infusion of diltiazem 3 mg/kg/24 h preoperatively and oral diltiazem for 3 months
Study: 8090335
Drug: Placebo 0.3
Normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.3 mg/kg bolus preoperatively, followed by infusion of placebo 3 mg/kg/24 h preoperatively and oral placebo for 3 months
Study: 26506778
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba injection combined with traditional therapy
Study: 26506778
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (control group)
Study: 21263198
Drug: Thyroid suppression
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid suppression therapy with thyroxine (T4) 2.5µg/kg/day for two months
Study: 19055284
Drug: Chinese drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drug (Wuzi Yanzong Pill)
Study: 16224108
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management with oxygen therapy (control group, n = 83)
Study: 12952258
Drug: AKITA system
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKITA system (inhalation device)
Study: 12952258
Drug: PARI‐LC Star
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARI‐LC Star (inhalation device)
Study: 12952258
Drug: HaloLite (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HaloLite (inhalation device)
Study: 12952258
Drug: Prolastin (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin (5% solution)
Study: 8458457
Drug: Follicular stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicular stimulation with CC in insemination cycles
Study: 8458457
Drug: Follicular stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicular stimulation with CC in intercourse cycles
Study: 3702643
Drug: Multiple vitamin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple vitamin, multiple mineral supplement containing 18 mg iron for 8 months
Study: 24260145
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for social anxiety disorder
Study: 20237361
Drug: High-dose extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose extracorporeal shockwave therapy
Study: 19009658
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g n‐3 polyunsaturated fatty acids (PUFA) from seal oils, three times a day, along with a recommended diet
Study: 19009658
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 g, three times a day, along with a recommended diet
Study: 24322182
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g daily
Study: 18302747
Drug: Letrozole treatment
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole treatment
Study: 25796103
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (n = 14) received 1.7 g protein/kg/day during admission and a daily protein supplement (18.8 g protein) and resistance training 3 times per week for 12 weeks after discharge
Study: 18177949
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intervention, specific dosage and duration not available
Study: 9917782
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia plus intracameral 1% preservative-free lidocaine
Study: 9917782
Drug: Intracameral balanced
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral balanced salt solution
Study: 2182208
Drug: Lidocaine treatment
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine treatment (100 mg bolus followed by 2 mg.kg-1 for at least the first 24 hours)
Study: 22084333
Drug: 90-Hz WBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-Hz WBV therapy
Study: 22084333
Drug: 30-Hz WBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-Hz WBV therapy
Study: 22084333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no WBV therapy)
Study: 17016233
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy and radiotherapy
Study: 15799931
Drug: Cypher drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cypher drug-eluting stents
Study: 8397489
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg once daily, administered either as a single dose or repeated for 2 to 6 days.
Study: 6973989
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluproquazone
Study: 6996931
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg paracetamol
Study: 29492612
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (two doses of 20 mg/kg)
Study: 29492612
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (two doses of 15 mg/kg)
Study: 20733096
Drug: Atrasentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan (10 mg)
Study: 11979505
Drug: calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium (500 mg day(‐1)) + calcitonin (nasal spray 100 U day(‐1))
Study: 10811549
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 100 mg
Study: 7149969
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 250 mg
Study: 21703724
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) at a frequency of 6 Hz for 5 consecutive days, daily series of 5 periods of 1 minute
Study: 12118758
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative respiratory therapy
Study: 28755409
Drug: REGN1193 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1193 (0.05 to 0.6 mg/kg)
Study: 28755409
Drug: REGN1193 (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1193 (0.6 mg/kg)
Study: 28755409
Drug: REGN1193 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1193 (all doses)
Study: 22850268
Drug: Sertindole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (mean dose=17 mg/day)
Study: 22850268
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose=16 mg/day)
Study: 15223075
Drug: High-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol cocoa drink (HFCD; 187 mg flavan-3-ols/100 ml)
Study: 15223075
Drug: Low-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol cocoa drink (LFCD; 14 mg/100 ml)
Study: 9285502
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of alpha-lipoic acid (ALA) 1,200 mg
Study: 9285502
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of alpha-lipoic acid (ALA) 600 mg
Study: 9285502
Drug: Hamburg Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamburg Pain Adjective List (HPAL) total scale with ALA 1,200 mg
Study: 9285502
Drug: Hamburg Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamburg Pain Adjective List (HPAL) total scale with ALA 600 mg
Study: 9285502
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of alpha-lipoic acid (ALA) 800 mg
Study: 23347721
Drug: Nebulized naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized naloxone (2 mg in 3 mL normal saline)
Study: 15671203
Drug: CHF3381 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF3381 (100, 200, and 400 mg twice daily for 2 weeks)
Study: 2956296
Drug: Isotretinoin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (various dosage schedules)
Study: 23706887
Drug: Building Our
Approvals — FDA: no, EMA: no, PMDA: no
Description: Building Our Solutions and Connections (BOSC) intervention
Study: 16818832
Drug: Peer counselor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer counselor intervention (weekly for 6 weeks)
Study: 11081343
Drug: Hemodialysis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis therapy
Study: 1844997
Drug: All beverages
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beverages (heart rate, rectal temperature, perceived exertion)
Study: 30632329
Drug: 0.2% bio-adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% bio-adhesive chlorhexidine gel
Study: 26849799
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation at 400 mg per day
Study: 18567081
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) suppository
Study: 15778427
Drug: lopinavir/ritonavir (800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (800/200 mg qd or 400/100 mg bid)
Study: 12028208
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with calcium alginate dressings (UrgoSorb) for 4 weeks followed by hydrocolloid dressings (Algoplaque) for 4 weeks
Study: 10375362
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified preterm formula (0.9 mg/dl iron)
Study: 10375362
Drug: Fortified term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified term formula (0.5 mg/dl iron)
Study: 10375362
Drug: Preterm formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm formula (0.9 mg/dl iron) followed by term formula (0.5 mg/dl iron)
Study: 2216187
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin administered intramuscularly
Study: 2216187
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin administered intravenously
Study: 319541
Drug: Metoprolol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 120 mg/d
Study: 319541
Drug: Metoprolol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 120 mg/d and 210 mg/d pooled results
Study: 7934973
Drug: Propranolol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 240 mg/d
Study: 319541
Drug: Propranolol 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 360 mg/d
Study: 24660151
Drug: Oral dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextrose 10% given at 3 and 6 hours prior to the operation
Study: 24343071
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with 40 mg parecoxib sodium and infiltration of 0.5% ropivacaine (20 mL)
Study: 24343071
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 mL) intravenously before anesthesia induction and infiltration of 0.5% ropivacaine (20 mL)
Study: 12139206
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (20 mg twice daily)
Study: 1463527
Drug: Loracarbef (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (400 mg b.i.d.)
Study: 1463527
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg t.i.d.)
Study: 6509782
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor blockade (domperidone 10 mg i.v.) in acromegalic subjects
Study: 6509782
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor blockade (domperidone 10 mg i.v.) in normal controls
Study: 6509782
Drug: Intramuscular growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular growth hormone (three injections of 4 IU) before domperidone
Study: 30083962
Drug: tivantinib 360
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tivantinib 360 mg PO BID
Study: 27234001
Drug: Can Do
Approvals — FDA: no, EMA: no, PMDA: no
Description: Can Do Treatment (CDT)
Study: 7621454
Drug: External radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External radiation therapy
Study: 28199397
Drug: Topical dorzolamide/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide/timolol
Study: 28199397
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide and topical dexamethasone